BPC-157 and the Peptide Problem: What Clinics Can No Longer Advertise

2026-07-31 · CompliancePilotAI.io

Peptide therapy went from bodybuilding forums to med spa menus in a few short years — and regulators followed it there. The names to know:

• BPC-157
• TB-500 (FDA lists it as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500")
• MOTS-c
• LL-37 (FDA lists it as "Cathelicidin LL-37")

Why they can't be compounded — the part that hasn't changed

Under section 503A, a compounder may only use a bulk drug substance that meets one of three conditions: it complies with a USP or NF monograph, it's a component of an FDA-approved drug product, or it appears on FDA's 503A Bulks List. None of these four peptides satisfies any of the three today. That single fact — not any watchlist — is what makes compounding them unlawful, and it's the framing to rely on, because it doesn't move when FDA reshuffles its nomination categories.

FDA had previously placed all four in category 2 of its interim policy, the category for substances that "may present significant safety risks." Those nominations were later withdrawn by the nominators, so the four now appear in a separate "nominated but withdrawn" table on the same FDA page rather than in the live category 2 list. FDA's written safety concerns about each of them remain published there — for BPC-157 and MOTS-c, that the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans"; for LL-37, additionally that nonclinical findings "suggest detrimental effects on male reproduction and that this drug can be protumorigenic in some tissues."

⚠ This is moving right now — and it moved on July 23, 2026. FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, TB-500 and KPV (8–6, one abstention each) and MOTS-c (7–5, two abstentions) for inclusion on the 503A Bulks List, over the objection of FDA's own reviewers. Semax and Epitalon also passed the following day; emideltide (DSIP) was voted down. LL-37 was not part of the vote.

None of this changes what is lawful today. Advisory committee recommendations are non-binding, FDA has gone against them before, and inclusion still requires notice-and-comment rulemaking — counsel quoted in trade coverage put that at roughly eight to twelve months. Until a final rule issues, all four peptides remain outside what section 503A permits, and the guidance below stands. Confirm the current position on FDA.gov before acting.

And note what a Bulks List win would and wouldn't do. Eligibility to compound a substance is not permission to advertise it for a disease. The uses FDA evaluated were narrow and clinical — ulcerative colitis for BPC-157, wound healing for TB-500, obesity and osteoporosis for MOTS-c. A practice page selling "BPC-157 injury recovery protocol" would still be promoting an unapproved use, whatever happens to the list.

Why the public menu is the problem

A clinic's website is the first exhibit in any enforcement file. A public services page listing "BPC-157 injury recovery protocol" does three things at once:

1. Advertises an unapproved drug. None of these peptides is a component of any FDA-approved product, and marketing them for healing or recovery is a claim of drug-level effect.
2. Documents intent. Investigators don't need to visit your clinic — your menu, pricing page, and Instagram archive establish what you're selling and why.
3. Implicates your compounding partner. Boards of pharmacy pay attention to which clinics are ordering flagged substances, and a public menu makes the supply chain easy to trace.

"But it's for wellness, not treatment"

Intended use is read from the marketing. "Supports tissue repair," "accelerates recovery," and "gut healing protocol" are all effect claims — the wellness framing doesn't neutralize them, and for a substance the FDA has already flagged, even neutral listings draw attention.

What to do

• Remove flagged peptides from all public-facing materials — service menus, pricing pages, social posts, Google Business categories.
• Talk to counsel before continuing to offer them at all. This is one of the categories where marketing cleanup and clinical decision-making are inseparable — which is why our scanner escalates these findings rather than suggesting a rewrite.
• Scientific discussion belongs in professional channels. Literature reviews and peer education are different from retail promotion — keep them off patient-facing web properties.

There is no compliant rewrite for a public BPC-157 listing. Some findings are about words; this one is about the offer itself.

This article is educational content about publicly available regulatory guidance. It is not legal advice; consult healthcare counsel for guidance specific to your practice.